Discovery of a Novel C0702 Restricted Epitope on MAGE A1 and Preclinical Development of an Enhanced TCR-T Cell Therapy

Explore a 31-minute webinar presented by Dr. Yifan Wang, Director for target discovery at TScan Therapeutics, on the discovery of a novel C0702 restricted epitope on MAGE A1 and its preclinical development. Delve into the potential of immune checkpoint therapy as an effective strategy to enhance T-cell anti-tumor activity, and learn about the identification of T-cell receptors and cancer antigens driving positive anti-tumor responses. Gain insights into how these discoveries could be developed into TCR-T cell therapy candidates, potentially extending anti-tumor benefits to patients sharing the same tumor antigens. Dr. Wang, with his extensive background in gene editing and a Ph.D. in Genetics from Harvard University, brings valuable expertise to this presentation on cutting-edge cancer immunotherapy research.

Discovery of a novel C0702 restricted epitope on MAGE A1 and pre clinical development of an enhanced